Pharmacodynamics of amlodipine: hemodynamic effects and antianginal efficacy after atrial pacing

K J Hogg1, R S Hornung, W S Hillis

  • 1Department of Materia Medica, University of Glasgow, Stobhill General Hospital, Scotland.

American Heart Journal
|November 1, 1989
PubMed

Insights

Intravenous amlodipine (10 mg) improved angina symptoms by increasing the anginal threshold and reducing ST segment changes. This vasodilator effect occurred without negatively impacting cardiac output or contractility.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Stable angina pectoris significantly impacts patient quality of life.
  • Current treatments aim to improve myocardial oxygen supply-demand balance.

Purpose of the Study:

  • To evaluate the hemodynamic effects and antianginal efficacy of intravenous amlodipine in stable angina patients.
  • To assess amlodipine's impact on exercise tolerance and cardiac workload.

Main Methods:

  • A randomized, placebo-controlled study involving 18 subjects with stable angina pectoris.
  • Intravenous administration of 10 mg amlodipine or placebo.
  • Hemodynamic monitoring (heart rate, blood pressure, cardiac output) and pacing-induced angina tests were performed.

Main Results:

  • Amlodipine significantly decreased systemic vascular resistance and mean arterial pressure.
  • Time to pacing-induced angina increased, indicating improved exercise tolerance.
  • Double product and ST segment shifts were reduced, signifying decreased myocardial oxygen demand during angina.

Conclusions:

  • Intravenous amlodipine demonstrates a vasodilator effect and enhances the anginal threshold in patients with stable angina.
  • The drug improves antianginal efficacy without adverse effects on cardiac contractility or output.

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...